Business Wire

Ipsen to Present New Insights at ASBMR for Potential Treatment of Ultra-rare Disease Fibrodysplasia Ossificans Progressiva (FOP), Including Global Phase III MOVE Trial Results

Share

Regulatory News:

Ipsen (Euronext: IPN: ADR: IPSEY) today announced that it will share data from the company’s growing Rare Diseases Therapeutic Area portfolio, with seven presentations at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting (September 11-15, 2020). These include the oral presentation of Ipsen’s MOVE trial (during the Novel Therapies for Rare Bone Disease session on Saturday, 12 September [11:00am - 12:15pm ET]), the first and only multicenter Phase III study in fibrodysplasia ossificans progressiva (FOP). The data will be presented by Dr Robert Pignolo, Division of Geriatric Medicine and Gerontology, Department of Internal Medicine, Mayo Clinic, and describes the trial outcomes of the oral investigational therapy palovarotene in reducing new heterotopic ossification (HO) volume in 107 pediatric and adult patients with FOP.1 The MOVE efficacy results were compared with data from untreated patients from Ipsen’s Natural History Study (NHS).2 Safety outcomes from the MOVE trial will also be presented.

“Our passion and commitment to understanding rare diseases has driven this research forward and we’re proud to present these data at the ASBMR 2020 Annual Meeting,” said Howard Mayer, M.D., Executive Vice President and Head of Research and Development at Ipsen. “Collaboration is critical with rare disease research and development and we look forward to continuing to work with key thought leaders, clinicians, the patient advocacy community, and regulatory authorities as we build on our research and develop potential therapeutic agents in rare diseases, including for patients with FOP.”

Additionally, four posters reporting data from the NHS will be presented. The NHS is the largest FOP study of this kind worldwide and is the first global, multicenter, longitudinal study designed to measure disease progression over three years.2 Findings from the NHS reinforce that measuring HO is a viable way to monitor changes in FOP and to assess a potential treatment effect over this time period.

Follow Ipsen on Twitter via @IpsenGroup and keep up to date with ASBMR 2020 conference news and updates by using the hashtag #ASBMR2020.

Overview of all Ipsen presentations at ASBMR 2020 Annual Meeting:

Medicine/disease

Abstract number/title

Study authors

Palovarotene/FOP

Palovarotene (PVO) for Fibrodysplasia Ossificans Progressiva (FOP): Data from the Phase III MOVE Trial

Robert J. Pignolo, Mona Al Mukaddam, Geneviève Baujat, Staffan K. Berglund, Angela M. Cheung, Carmen De Cunto, Patricia Delai, Maja Di Rocco, Nobuhiko Haga, Edward C. Hsiao, Peter Kannu, Richard Keen, Edna E. Mancilla, Donna R. Grogan, Rose Marino, Andrew Strahs, Frederick S. Kaplan

Palovarotene/FOP

Measuring outcomes in ultra-rare bone diseases: Methodology of the palovarotene fibrodysplasia ossificans progressiva (FOP) clinical development program

Robert J. Pignolo, Geneviève Baujat, Matthew A. Brown, Carmen De Cunto, Maja Di Rocco, Edward C. Hsiao, Richard Keen, Mona Al Mukaddam, Andrew Strahs, Donna R. Grogan, Rose Marino, Frederick S. Kaplan

FOP

Medications used by individuals with Fibrodysplasia Ossificans Progressiva (FOP): Data from a global natural history study

Richard Keen, Mona Al Mukaddam, Geneviève Baujat, Carmen De Cunto, Edward C. Hsiao, Robert J. Pignolo, Kathleen Harnett, Rose Marino, Frederick S. Kaplan

FOP

Longitudinal and flare-up-specific biomarkers in fibrodysplasia ossificans progressiva (FOP): Data from a global natural history study

Robert J. Pignolo, Mona Al Mukaddam, Geneviève Baujat, Carmen De Cunto, Edward C. Hsiao, Richard Keen, Kathleen Harnett, Rose Marino, Frederick S. Kaplan

FOP

Use of assistive devices and adaptations by individuals with fibrodysplasia ossificans progressiva (FOP): Data from a global natural history study

Edward C. Hsiao, Mona Al Mukaddam, Geneviève Baujat, Carmen De Cunto, Richard Keen, Robert J. Pignolo, Kathleen Harnett, Rose Marino, Frederick S. Kaplan

FOP

A global natural history study of fibrodysplasia ossificans progressiva (FOP): 12-month outcomes

Mona Al Mukaddam, Robert J. Pignolo, Geneviève Baujat, Matthew A. Brown, Carmen De Cunto, Maja Di Rocco, Edward C. Hsiao, Richard Keen, Kim-Hanh Le Quan Sang, Andrew Strahs, Rose Marino, Frederick S. Kaplan

FOP

Validity and reliability of the fibrodysplasia ossificans progressiva physical function questionnaire (FOP-PFQ), a patient-reported, disease-specific measure

Robert J. Pignolo, Miriam Kimel, John Whalen, Ariane Kawata, Dennis Revicki, Rose Marino, Frederick S. Kaplan

About palovarotene

Palovarotene is an oral investigational, selective RARγ agonist being developed as a potential treatment for patients with the debilitating ultra-rare, genetic disorder fibrodysplasia ossificans progressiva (FOP). Palovarotene, which had rare pediatric disease and breakthrough therapy designations for the treatment of FOP, was acquired by Ipsen through the acquisition of Clementia Pharmaceuticals in April 2019.

About fibrodysplasia ossificans progressiva (FOP)

Fibrodysplasia ossificans progressiva (FOP) is an ultra-rare, genetic disorder characterized by bone that forms outside the normal skeleton, in muscles, tendons or soft tissue.3 FOP is among the rarest of human diseases, and while there are approximately 1,000 described cases globally, the reported prevalence of FOP is estimated at approximately 1.36 per million individuals.4,5

About Ipsen

Ipsen is a global specialty-driven biopharmaceutical group focused on innovation and Specialty Care. The Group develops and commercializes innovative medicines in three key therapeutic areas – Oncology, Neuroscience, and Rare Diseases. Ipsen also has a well-established Consumer Healthcare business. With total sales over €2.5 billion in 2019, Ipsen sells more than 20 drugs in over 115 countries, with a direct commercial presence in more than 30 countries. Ipsen’s R&D is focused on its innovative and differentiated technological platforms located in the heart of the leading biotechnological and life sciences hubs (Paris-Saclay, France; Oxford, UK; Cambridge, US). The Group has about 5,800 employees worldwide. Ipsen is listed in Paris (Euronext: IPN) and in the United States through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information on Ipsen, visit www.ipsen.com

Ipsen’s Forward Looking Statement

The forward-looking statements, objectives and targets contained herein are based on the Group’s management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. All of the above risks could affect the Group’s future ability to achieve its financial targets, which were set assuming reasonable macroeconomic conditions based on the information available today. Use of the words "believes", "anticipates" and "expects" and similar expressions are intended to identify forward-looking statements, including the Group’s expectations regarding future events, including regulatory filings and determinations, and the outcome of this study or other studies. Moreover, the targets described in this document were prepared without taking into account external growth assumptions and potential future acquisitions, which may alter these parameters. These objectives are based on data and assumptions regarded as reasonable by the Group. These targets depend on conditions or facts likely to happen in the future, and not exclusively on historical data. Actual results may depart significantly from these targets given the occurrence of certain risks and uncertainties, notably the fact that a promising product in early development phase or clinical trial may end up never being launched on the market or reaching its commercial targets, notably for regulatory or competition reasons. The Group must face or might face competition from generic products that might translate into a loss of market share. Furthermore, the Research and Development process involves several stages each of which involves the substantial risk that the Group may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Group cannot be certain that favorable results obtained during preclinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. There can be no guarantees a product will receive the necessary regulatory approvals or that the product will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Other risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of 6 pharmaceutical industry regulation and health care legislation; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the Group's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Group’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The Group also depends on third parties to develop and market some of its products which could potentially generate substantial royalties; these partners could behave in such ways which could cause damage to the Group’s activities and financial results. The Group cannot be certain that its partners will fulfil their obligations. It might be unable to obtain any benefit from those agreements. A default by any of the Group’s partners could generate lower revenues than expected. Such situations could have a negative impact on the Group’s business, financial position or performance. The Group expressly disclaims any obligation or undertaking to update or revise any forward-looking statements, targets or estimates contained in this press release to reflect any change in events, conditions, assumptions or circumstances on which any such statements are based, unless so required by applicable law. The Group’s business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers. The risks and uncertainties set out are not exhaustive and the reader is advised to refer to the Group’s 2019 Universal Registration Document available on its website (www.ipsen.com).

References

  1. Pignolo R et al. Palovarotene (PVO) for fibrodysplasia ossificans progressiva (FOP): Data from the phase III MOVE trial. ASBMR September 2020.
  2. Al Mukaddam M et al. A Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 12-Month Outcomes. J Endocr Soc. 2020;4 (Supplement 1):OR29-05
  3. The Medical Management of Fibrodysplasia Ossificans Progressiva: Current Treatment Considerations, IFOPA. Accessed: May 2020. Available: http://fundacionfop.org.ar/wp-content/uploads/2019/05/GUIDELINES-May-2019.pdf
  4. Lilijesthrom M & Bogard B. The Global Known FOP Population. Presented at the FOP Drug Development Forum. Boston, MA; 2016.
  5. Baujat et al. Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: an estimate based on a record linkage of two national databases. Orphanet Journal of Rare Diseases. 2017; 12:123.

Contact information

Media
Jess Smith
Senior Director, Global Franchise Communications
+44 (0) 7557 267634
jess.smith@ipsen.com

Maryann Quinn
Director, Product Communications
North America
1-857-529-1151
Maryann.quinn@ipsen.com

Financial Community
Eugenia Litz
Vice President, Investor Relations
+44 (0) 1753 627721
eugenia.litz@ipsen.com

Myriam Koutchinsky
Investor Relations Manager
+33 (0)1 58 33 51 04
myriam.koutchinsky@ipsen.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Little Cinema Taps Verimatrix To Secure Hollywood’s Virtual Premiere Events30.11.2020 17:45:00 CETPress release

Regulatory News: Verimatrix, (Paris:VMX), the leader in powering the modern connected world with people-centered security, today announced that New York-based Little Cinema deployed Verimatrix Watermarking and Multi-DRM technologies for its virtual premieres and previews. A groundbreaking digital studio, Little Cinema has partnered with Netflix, ABC, CBS, HBO Max, and Warner Media to produce state-of-the-art virtual premiere events for an industry that used to rely solely on in-person debuts. To fulfill the enhanced protection requirements for this high-value early-release content, Little Cinema looked to Verimatrix and its Secure Cloud. These innovative and highly-interactive virtual streaming events have made waves in Hollywood, earning the studio recognition in BBC News, Vogue, Variety, Vanity Fair, The Hollywood Reporter, and more. “Verimatrix supplies us with the needed anti-piracy protections and overall peace of mind that Hollywood studios demand when switching to virtual events

Emory University to Host a Live Webcast With His Holiness the Dalai Lama30.11.2020 16:39:00 CETPress release

The Center for Contemplative Science and Compassion-Based Ethics at Emory University will host a live webinar with His Holiness the Dalai Lama on Tuesday, December 8, 2020. A discussion titled “The Necessity of Compassion for the Survival of Humanity” will feature the Dalai Lama in conversation with Melani A. Walton, co-founder of the Rob and Melani Walton Foundation, and Dr. Sanjay Gupta, chief medical correspondent for CNN. (For speaker photos click here.) The webcast begins at 10:30pm ET on Dec. 8, 2020 (Dec. 9 @ 9:00am India Standard Time) and will be simulcast in 14 languages. It is FREE of charge and open to anyone who’d like to participate. Advance registration is encouraged at https://compassionshift.emory.edu. “With so many urgent concerns impacting our world, the time is right to start a global conversation about the importance of compassion,” said Lobsang Tenzin Negi, executive director of Emory University’s Center for Contemplative Science and Compassion-Based Ethics. “For

Flexjet Advances European Expansion with Delivery of First Embraer Praetor 60030.11.2020 15:03:00 CETPress release

Flexjet Ltd., offering travelers access to the world’s most luxurious fleet of private jets, accepted delivery of the first Praetor 600 aircraft in its European-based fleet, marking a significant milestone in the expansion of the company’s global business. Flexjet is the only shared-ownership/fractional provider of the Praetor 600, part of a US$1.4 billion order for Embraer Executive Jets, a division of Embraer S.A. (NYSE: ERJ; BM&FBOVESPA: EMBR3), that was announced in October 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005564/en/ Flexjet Embraer Praetor 600 super midsized aircraft part of the European-based Flexjet fleet. (Photo: Business Wire) European Managing Director Marine Eugène leads the team headquartered at Flexjet House in the Mayfair neighbourhood in the west end of London. In addition, Flexjet has opened facilities including a European Tactical Control Centre in the United Kingdom to coordinate f

Diamond Standard Commodity and Token to List on INX30.11.2020 15:00:00 CETPress release

INX Limited, the blockchain-based platform for trading digital securities and cryptocurrencies, announces today that it has signed a letter of intent with Diamond Standard to list the world’s first diamond commodity—the Diamond Standard Coin. The Coin is a digital and physical asset: a standardized set of diamonds with a wireless chip enabling it to trade as a token on the INX trading platform. The availability of the Coin on the INX platform is pending regulatory approval for the $25 million initial public commodity offering. This diamond commodity makes a $1.2 trillion hard asset available to institutional investors for the first time. Diamond Standard recently announced its plan to launch an ETF on the NYSE under the ticker DIAM, and an agreement to list futures on the CME Globex via the MGEX. INX is providing an electronic spot market for the Diamond Standard Coin. Investors who acquire a Diamond Standard Token on the INX platform are transacting the physical commodity itself, and

Kymeta™ Announces Commercial Availability of its Next-Generation Antenna, Terminal, and Services Making Mobile Global30.11.2020 15:00:00 CETPress release

Kymeta (www.kymetacorp.com)—the communications company making mobile global—announced that the Kymeta™ u8 and Kymeta Connect™ are available for government and commercial purchase after November 30, 2020, unlocking the potential of broadband satellite connectivity and cellular networks to satisfy the overwhelming demand for communications on the move. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201130005022/en/ Kymeta’s next-generation solutions are built for mobility and designed to meet the needs of global defense agencies, government, first responders, and commercial customers. Kymeta’s products and services have been field deployed for three years and the demand for the Kymeta u8 presales has already exceeded expectations. With the introduction of the Kymeta u8, the company has meaningfully increased antenna throughput and significantly reduced the total cost of ownership. Kymeta’s new products and services offer a bre

Inversago Pharma Continues to Rapidly Expand Its Leadership Team and Appoints Glenn D. Crater, MD, FCCP as Chief Medical Officer30.11.2020 14:00:00 CETPress release

Inversago Pharma Inc. (“the Company” or “Inversago”), the peripheral CB1 blockade company, today announced it has appointed Glenn D. Crater, MD, FCCP as its Chief Medical Officer. In this position, Dr. Crater will oversee the clinical development of Inversago’s lead compound for Prader-Willi syndrome, INV-101, as well as its pipeline of other peripherally-acting CB1 inverse agonists in several other indications. “The appointment of a Chief Medical Officer is an essential element of our corporate strategy as we have entered the clinical phase with our lead compound”, said François Ravenelle, PhD, CEO and founder of Inversago Pharma. “Glenn brings a broad range of relevant experiences in all aspects of drug development and regulatory interactions and I trust he will have a strong impact on the science we develop at Inversago, helping us meet our objective: developing safe and potent inverse agonists of peripheral CB1 receptors”, added Dr. Ravenelle. “I am very excited to join Inversago a